AX-2026-041283

Semaglutide · 2 mg declared · Wuhan Wansheng Biotechnology Co., Ltd. · lot WWB-2603-N3120

MARGINALIDENTITY CONSISTENT

Report ID: AX-2026-041283
Compound: Semaglutide
Compound class: Incretin analogues and co-agonists
Supplier: WWB — Wuhan Wansheng Biotechnology Co., Ltd.
Batch / lot: WWB-2603-N3120
Declared label claim: 2mg
Laboratory: Janoshik Analytical
Assay date: 30 Apr 2026
Submitted: 20 May 2026
Quarter: 2026-Q2
Submitter: h.beaulieu
Sample provenance: Buyer-sourced

Section 1

Results

Measured against the index acceptance specification for the incretin analogues and co-agonists class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	99.48	% area	≥ 97.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.52	% area	≤ 3.0	PASS
Largest single impurity	RP-HPLC — des-AEEA semaglutide (−145 Da)	0.21	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	4111.0524	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	4111.0516	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	-0.2	ppm	± 15	PASS
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	7.04	%	≤ 8.0	PASS
Counter-ion (TFA)	anion-exchange ion chromatography	7.20	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.56	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear after 90 s gentle swirling, no particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	3.33	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	18.48	min	18.42 ± 0.45 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.21	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	60,025	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-Aib8]-diastereomer	0.78	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 60,025, and skew follows the reported asymmetry factor of 1.21. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.21 % impurity against a 99.48 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Semaglutide — main peak	18.48	4,835,036	99.48	—
2	des-AEEA semaglutide (−145 Da)	17.66	10,207	0.21	-145.074
3	[D-Aib8]-diastereomer	18.24	7,290	0.15	0.000
4	des-His1 truncate (−137 Da)	17.34	3,888	0.08	-137.059
5	tBu-protected residual (+56 Da)	20.53	3,888	0.08	+56.063
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 4111.0524 Da, computed from C187H291N45O59. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 4111.0516 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
6+	686.1827	686.1825	-0.0002	8.4
5+	823.2178	823.2176	-0.0002	52.6
4+	1028.7704	1028.7702	-0.0002	100.0
3+	1371.3581	1371.3578	-0.0003	54.3
2+	2056.5335	2056.5331	-0.0004	8.3

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.12	99.48	divergence +0.08 pp vs batch median
Total impurities (% area)	1.21	0.52
Largest single impurity (% area)	0.64	0.21
Water (%)	5.8	7.04
Counter-ion (%)	not stated	7.20
Peptide content (%w/w)	99.2	not determined
Endotoxin (EU/mg)	not stated	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (ambient, 1 d) → laboratory (hand-carried, 5 d) → assay.
Assay date: 30 Apr 2026
Submitted to the index: 20 May 2026
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: IDENTITY CONSISTENT

What this report does not establish

How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 4

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

sodium_adduct20 May 2026

Identity confirmed and purity at 99.48 %. The two answer different questions — what it is, and how much else is in it — and a record carrying both is the version worth citing.

charge_envelope20 May 2026

Identity confirmed, purity 99.48 %, mass balance closed. This record is complete against the index definition of complete and there is nothing outstanding on it.

quad_unit20 May 2026

The index grades identity by instrument class, not by the ppm figure alone: "confirmed" where the determination was made at high resolution, "consistent with" where it was not. The status block above says which applies to this record, and it is worth reading before the number.

valley_drop20 May 2026

des-AEEA semaglutide (−145 Da) at 0.21 % elutes close enough to the main peak that drop-line and valley-to-valley will not agree. The index prints the resolution figure and applies no criterion to it — how close the nearest impurity sits is a property of the compound and the gradient, not of the system. What matters is that the convention used is stated.

Section 7

Related records

Same batch — lot WWB-2603-N3120 n=15

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041284	WWB-2603-N3120	Medutest	2026-Q2	98.81	6.47	—	Buyer-sourced	1	MARGINAL
AX-2026-041285	WWB-2603-N3120	Janoshik	2026-Q2	98.46	6.94	99.0	Buyer-sourced	1	MARGINAL
AX-2026-041286	WWB-2603-N3120	VendorInvestigate	2026-Q2	98.37	6.65	94.7	Buyer-sourced	1	MARGINAL
AX-2026-041287	WWB-2603-N3120	Nordanalyt	2026-Q2	98.81	6.69	—	Buyer-sourced	1	MARGINAL
AX-2026-041288	WWB-2603-N3120	Janoshik	2026-Q2	99.04	5.93	—	Buyer-sourced	1	MARGINAL
AX-2026-041289	WWB-2603-N3120	PeptideMeter	2026-Q2	99.15	5.76	90.8	Buyer-sourced	1	MARGINAL
AX-2026-041290	WWB-2603-N3120	Nordanalyt	2026-Q2	98.88	6.66	90.7	Buyer-sourced	1	MARGINAL
AX-2026-041291	WWB-2603-N3120	Nordanalyt	2026-Q2	99.07	6.71	—	Buyer-sourced	1	MARGINAL
AX-2026-041292	WWB-2603-N3120	PeptideMeter	2026-Q2	98.91	6.69	99.1	Buyer-sourced	1	MARGINAL
AX-2026-041293	WWB-2603-N3120	VendorInvestigate	2026-Q2	99.08	5.90	97.7	Buyer-sourced	1	MARGINAL
AX-2026-041294	WWB-2603-N3120	VendorInvestigate	2026-Q2	99.36	6.20	—	Buyer-sourced	2	FAIL
AX-2026-041295	WWB-2603-N3120	PeptideMeter	2026-Q2	99.07	6.35	—	Buyer-sourced	1	MARGINAL
AX-2026-041296	WWB-2603-N3120	Kestrel	2026-Q2	99.37	6.89	91.7	Buyer-sourced	1	MARGINAL
AX-2026-041297	WWB-2603-N3120	PeptideMeter	2026-Q2	98.63	7.02	93.1	Buyer-sourced	1	MARGINAL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Semaglutide records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043376	WXT	WXT-2604-C3248	Janoshik	2026-Q3	97.08	4.22	—	Buyer-sourced	1	MARGINAL
AX-2026-042424	Homopeptide	HOMO-2604-X3806	PeptideMeter	2026-Q3	98.85	4.87	92.0	Buyer-sourced	0	PASS
AX-2026-041643	FGP	FGP-2602-M8547	Janoshik	2026-Q3	99.31	2.79	100.7	Buyer-sourced	0	PASS
AX-2026-041334	WWB	WWB-2606-N3192	Janoshik	2026-Q3	98.93	4.62	99.9	Buyer-sourced	0	PASS
AX-2026-042002	AMB	AMB-2607-N6274	VendorInvestigate	2026-Q3	98.23	6.37	97.1	Buyer-sourced	1	MARGINAL
AX-2026-041337	WWB	WWB-2606-N3192	Nordanalyt	2026-Q3	99.52	3.92	—	Buyer-sourced	0	PASS
AX-2026-042595	HJ	HJ-2608-C7002	Janoshik	2026-Q3	99.50	3.55	—	Buyer-sourced	1	MARGINAL
AX-2026-042217	TFC	TFC-2604-X9037	PeptideMeter	2026-Q3	98.95	4.61	96.9	Buyer-sourced	0	PASS

Other recent WWB records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041275	Liraglutide	WWB-2607-X2189	Nordanalyt	2026-Q3	99.33	4.39	—	Buyer-sourced	1	MARGINAL
AX-2026-041334	Semaglutide	WWB-2606-N3192	Janoshik	2026-Q3	98.93	4.62	99.9	Buyer-sourced	0	PASS
AX-2026-041337	Semaglutide	WWB-2606-N3192	Nordanalyt	2026-Q3	99.52	3.92	—	Buyer-sourced	0	PASS
AX-2026-041335	Semaglutide	WWB-2606-N3192	Janoshik	2026-Q3	99.15	4.27	98.9	Buyer-sourced	0	PASS
AX-2026-041271	Liraglutide	WWB-2607-X2189	Medutest	2026-Q3	99.52	4.57	97.4	Buyer-sourced	1	MARGINAL
AX-2026-041328	Semaglutide	WWB-2606-N3192	Janoshik	2026-Q3	98.99	4.47	106.1	Buyer-sourced	0	PASS
AX-2026-041333	Semaglutide	WWB-2606-N3192	Janoshik	2026-Q3	99.18	4.51	90.4	Laboratory-retained	0	PASS
AX-2026-041273	Liraglutide	WWB-2607-X2189	Janoshik	2026-Q3	99.31	5.52	104.8	Buyer-sourced	1	MARGINAL